Wall Street Journal -- Genzyme Corp. expects to stop rationing its rare-disease treatment Fabrazyme during the first half of next year, ending a shortage that began in 2009.
Wall Street Journal -- Genzyme Corp. expects to stop rationing its rare-disease treatment Fabrazyme during the first half of next year, ending a shortage that began in 2009.
